Xiidra plus Miebo could improve dry eye in patients who tried other therapies
Bausch + Lomb's Xiidra and Miebo combination therapy significantly improved dry eye symptoms in patients who had previously tried over four treatments. A study of 68 patients showed reduced dryness, improved staining, and better tear metrics. Most patients continued using both drops for about 194 days. Bausch + Lomb plans a phase 3 study for a combined drop.
How this was made
The 30-second read
Why it matters
The data provides early evidence of efficacy, which could de‑risk the upcoming trial and support a future product launch.
Market read
First public disclosure of combination therapy data could move BHC stock and influence the dry‑eye therapeutic space.
What to watch
Potential competition from other dry‑eye combos and reimbursement uncertainties may limit upside.
Background
Bausch Health announced a Phase 3 evaluation of a dual‑action dry‑eye therapy after presenting retrospective real‑world data at Academy 2026.
Ticker impact
Article reports first real‑world data on the Xiidra + Miebo combination and announces a Phase 3 study, a new catalyst for Bausch Health (BHC).
likely upside as market prices in the Phase 3 prospect.
First disclosure of supportive real‑world outcomes and a Phase 3 plan is material for BHC's ophthalmology pipeline.
Market effects
May boost the ophthalmic therapeutics sector and related dry‑eye drug peers.
US biotech market could see modest buying pressure.
Highlights continued innovation in eye‑care treatments worldwide.
Counterpoint
If the Phase 3 fails to meet endpoints, the initial enthusiasm could reverse sharply.
Key entities
- companyBausch Health Companies Inc.
US‑listed ophthalmic drug developer (ticker BHC).
- drugXiidra
Lifitegrast ophthalmic solution owned by Bausch Health.
- drugMiebo
Perfluorohexyloctane ophthalmic solution combined with Xiidra.
